Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer

NCT02318901 | Terminated Phase 1 Results FDA Drug

• 1 other identifier: PembroMab
• Study Type: interventional
• Target: 16
• Locations: 1 country
• Sites: 1

Brief Summary

There will be two phase II cohorts for pembro plus trastuzumab: one cohort will be for patients with unresectable HER2 overexpressing gastric or GEJ cancers, the other cohort will be for patients with HER2 overexpressing metastatic breast cancer (MBC). The pembro plus ado-trastuzumab emtansine phase II arm will be for patients with HER2 overexpressing MBC. There will be two phase II cohorts for pembro plus cetuximab: one cohort will be for patients with HNSCC, the other cohort will be for patients with K-ras, B-raf, N-ras wildtype metastatic CRC.

Conditions

Advanced Cancer; Breast Cancer; Gastric Cancer; Esophageal Cancer; Colorectal Cancer

Outcome Measures

Primary Outcomes (1)

• Determine the Recommended Phase 2 Dose (RP2D) of Monoclonal Antibody Therapy (Mab) in Combination With Pembrolizumab (Pembro) in Subjects With Advanced Cancer

  PI left site. Study was prematurely terminated. No additional study items were conducted including, data collection, results or statistical analysis completed.

  3 weeks

Secondary Outcomes (5)

• Frequency of Grade 3 or Higher Treatment-related Adverse Events by CTCAE 4.03

  up to 12 months

• Response Rate by irRC and Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Criteria

  12 weeks

• To Determine the Overall Survival (OS) and Progression-free Survival (PFS)

  up to 12 months

• To Characterize Changes in Circulating Tumor DNA in Patients Enrolled on This Study

  up to 12 months

• Textural Changes Identified on Imaging That is Done Per Routine Practice

  12 weeks

Study Arms (3)

Arm 1

EXPERIMENTAL

Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks. Intravenous (i.v.) trastuzumab 6 mg/kg on day 1 every 21 days.

Drug: Pembrolizumab; Drug: Trastuzumab

Arm 2

EXPERIMENTAL

Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks. i.v. ado-trastuzumab emtansine 3.6 mg/kg on day 1 every 21 days.

Drug: Pembrolizumab; Drug: ado-trastuzumab emtansine

Arm 3

EXPERIMENTAL

Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks. i.v. cetuximab 400 mg/m2 on cycle 1 day 1, then i.v. cetuximab 250 mg/m2 on day 8. Each subsequent cycle will be i.v. cetuximab 250 mg/m2 on days 1 and 8 every 21 days.

Drug: Pembrolizumab; Drug: Cetuximab

Interventions

Pembrolizumab DRUG

Also known as: KEYTRUDA

Arm 1; Arm 2; Arm 3

Trastuzumab DRUG

Also known as: Herceptin

Arm 1

ado-trastuzumab emtansine DRUG

Also known as: Kadcyla

Arm 2

Cetuximab DRUG

Also known as: Erbitux

Arm 3

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patient has definitive histologically or cytologically confirmed unresectable or metastatic solid tumor.
• Patient has one or more tumor measurable as defined by RECIST 1.1 by CT scan (or PET/CT, if patient is allergic to CT contrast media).
• Patients can be enrolled only on one of the treatment arms on this trial.
• The investigator will select the appropriate treatment arm for the patient with the following requirements: (a) Patients cannot have had prior progression or intolerance to a specific Mab and then enrolled on an arm with that same Mab plus pembro, (b) The Mab on the arm selected must be considered standard of care or listed in the NCCN guidelines (www.nccn.org) for that cancer type. For Arm 1, patients with HER2 overexpressing MBC eligible for maintenance trastuzumab are allowed after taxane plus trastuzumab plus pertuzumab combination therapy.
• Have recovered from acute toxicities of prior treatment:
• \> 3 weeks must have elapsed since receiving any investigational agent.
• \> 2 weeks must have elapsed since receiving any radiotherapy, or ≥ 3 weeks or 5 half-lives whichever is shorter for treatment with cytotoxic or biologic agents ( ≥ 6 weeks for mitomycin or nitrosoureas). Chronic treatment with non-investigational gonadotropin-releasing hormone analogs or other hormonal or supportive care is permitted.
• Patient has adequate biological parameters as demonstrated by the following blood counts at time of screening:
• Absolute neutrophil count (ANC) \> 1500 mm3, platelet count ≥ 100×109 L, hemoglobin ≥ 9 g/dL.
• Serum creatinine ≤2.0, total bilirubin ≤ 2 mg/dL, AST/ALT ≤ 5 times the upper limit of normal (ULN) range
• Thyroid stimulating hormone (TSH) within institutional normal limits. If TSH is above the upper limit of normal range, then a free T4 within institutional normal limits is acceptable.
• Persistent prior systemic therapy non-hematologic AE grade ≥ 2 (except alopecia or correctable electrolyte abnormality with supplementation)
• Patient has a Karnofsky performance status (KPS) ≥ 70.
• Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must be willing to use an acceptable contraceptive method (abstinence, oral contraceptive or double barrier method) for the duration of the study and for 30 days following the last dose of study drug, and must have a negative urine or serum pregnancy test within 2 weeks prior to beginning treatment on this trial.
• Patients must have unresectable HER2 overexpressing gastric or GEJ cancers to be enrolled on Cohort 1 of the pembro plus trastuzumab phase II portion.

You may not qualify if:

• Active clinically serious infection \> CTCAE (version 4.03) Grade 2.
• Serious non-healing wound, ulcer, or bone fracture.
• Patient has known brain metastases, unless previously treated and well-controlled for at least 1 month (defined as clinically stable, no edema, no steroids and stable in 2 scans at least 4 weeks apart).
• Inability to complete informed consent process and adhere to the protocol treatment plan and follow-up requirements.
• Patient has known active infection with HIV, hepatitis B, or hepatitis C (patients are NOT required to be tested for the presence of such viruses prior to therapy on this protocol).
• Requiring daily corticosteroid dose ≥ 10 mg prednisone or equivalent per day.
• Patient has undergone major surgery, other than diagnostic surgery (e.g., surgery done to obtain a biopsy for diagnosis without removal of an organ), within 4 weeks prior to Day 1 of treatment in this study.
• Patient has a history of allergy or hypersensitivity to any of the study drugs or any of their excipients, or the patient exhibits any of the events outlined in the Contraindication or Special Warnings and Precautions sections of the product or comparator SmPC or Prescribing Information.
• Patient has serious medical risk factors involving any of the major organ systems, or serious psychiatric disorders, which could compromise the patient's safety or the study data integrity.
• Patient will be receiving any other anti-cancer therapy during participation in this trial.
• Prior treatment with pembro. Receipt of other PD-1 inhibitors or PD-L1 inhibitors is allowed.
• Active or prior documented autoimmune disease requiring systemic treatment within the past 2 years.
• \. Patients with a history of more than one primary cancer, with the exception of: a) curatively resected nonmelanomatous skin cancer; b) curatively treated cervical carcinoma in-situ; or c) other primary solid tumor treated with curative intent and no known active disease present and no treatment administered during the 2 years prior to enrollment.

Sponsors & Collaborators

• Western Regional Medical Center: lead

Study Sites (1)

Western Regional Medical Center/Cancer Treatment Center of America

Goodyear, Arizona, 85338, United States

Location

MeSH Terms

Conditions

Breast Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Colorectal Neoplasms

Interventions

pembrolizumab; Trastuzumab; Ado-Trastuzumab Emtansine; Cetuximab

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases; Gastrointestinal Neoplasms; Digestive System Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Stomach Diseases; Head and Neck Neoplasms; Esophageal Diseases; Intestinal Neoplasms; Colonic Diseases; Intestinal Diseases; Rectal Diseases

Intervention Hierarchy (Ancestors)

Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Serum Globulins; Globulins; Maytansine; Macrolides; Lactones; Organic Chemicals; Lactams, Macrocyclic; Macrocyclic Compounds; Polycyclic Compounds

Results Point of Contact

• Title: Jessica L. Coats
• Organization: WRMC

jessica.coats@ctca-hope.com

623-207-3899

Study Officials

• Jordan Waypa, FNP

  Western Regional Medical Center

  STUDY DIRECTOR

• Alan Tan, MD

  Western Regional Medical Center

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 8, 2014
• First Posted: December 17, 2014
• Study Start: October 1, 2014
• Primary Completion: August 1, 2018
• Study Completion: August 1, 2018
• Last Updated: October 21, 2019
• Results First Posted: November 2, 2018

Record last verified: 2019-10

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)